Care homes, community & homecare
Medicines programmes cross places of care. Responsibility and practical follow-through need to travel with them.
In development · Intended scope and questions for evaluation
The organisation.
The people around it.
A monitoring plan needs an agreed requesting role, reviewing role and escalation route. A document being sent does not establish that the receiving team has accepted the work.
The people involved
Care homes, domiciliary care, community providers, specialist homecare services and their clinical and operational partners.
The dependencies
Residents and carers, care-home staff, community nursing, GPs, specialist prescribers, pharmacy and homecare providers.
What to examine
Accepted responsibilities, communications, monitoring and escalation, staff time, service continuity and the burden on people receiving care.
An illustrative set of programme relationships. The actual participants, authority, funding and permissions must be established for the defined setting. Explore every organisation perspective.
The decision worth examining.
What would make a defined medicines handover, monitoring or service arrangement workable across these settings?
A monitoring plan needs an agreed requesting role, reviewing role and escalation route. A document being sent does not establish that the receiving team has accepted the work.
Develop the programme around the setting.
Begin with the local need, relevant evidence, existing work and an agreed comparison. A proposed programme needs clear activities, alternatives, resources and reasons to revise or reject it.
Accepted responsibilities, communications, monitoring and escalation, staff time, service continuity and the burden on people receiving care.
Give each participant a workable role.
Residents and carers, care-home staff, community nursing, GPs, specialist prescribers, pharmacy and homecare providers.
The overall case and the position of each necessary participant deserve separate examination. Staff time, cash timing, capacity, access, commitments and full costs can change which arrangement is practical.
Make the evaluation useful to a decision.
Identify an accountable sponsor, the current process, the permitted information and what a worthwhile finding would allow the organisation to decide. Include preparation, checking, correction, implementation and support in the comparison.
PHARMORIS is in development. This page describes intended scope and a possible evaluation conversation; it does not establish customers, operational deployment, clinical validation or realised benefit.
Bring the question
your organisation
needs to move.
Tell us where the programme gets stuck, who is affected and what a worthwhile evaluation would help you decide.
Discuss a PHARMORIS evaluationAn initial conversation should describe the organisational question. Agree the purpose and information requirements before sharing records.